Table 4. Mean area under the effect curve (pH·min) following the oral administration of YH4808 and esomeprazole for 14 days.
| Parameters | Treatment | |||
|---|---|---|---|---|
| 100 BID | 200 QD | 200 BID | R40 BID | |
| AUEC (0–24 h) | 7,874.8 ± 1,117.3 | 7,355.4 ± 974.5 | 7,993.1 ± 1,008.7 | 7,704.2 ± 724.3 |
| ΔAUEC (0–24 h) | 4,744.8 ± 814.0 | 4,216.5 ± 859.4 | 5,492.8 ± 970.8 | 4,950.6 ± 1,060.8 |
| AUEC (5–12 h) | 2,424.8 ± 370.9 | 2,453.6 ± 279.3 | 2,549.6 ± 396.7 | 2,346.5 ± 273.0 |
| ΔAUEC (5–12 h) | 1,706.8 ± 347.1 | 1,703.4 ± 339.4 | 1,953.2 ± 359.3 | 1,683.8 ± 422.1 |
Data are presented as mean ± standard deviation. There was no statistically significant difference among the groups (p > 0.05).
ΔAUEC, day 14 – baseline; 100 BID, YH4808 100 mg twice daily for 14 days; 200 QD, YH4808 200 mg once daily for 14 days; 200BID, YH4808 200 mg twice daily for 14 days; R40 BID, esomeprazole 40 mg twice daily for 14 days.